Louisiana Attorney General Buddy Caldwell has filed a civil action lawsuit against pharmaceutical giant GlaxoSmithKline for wrongfully and illegally marketing, pricing, promoting and selling its diabetes medication, according to a news release from the office of the AG.
Rosiglitazone maleate, the diabetes medication, was allegedly marketed under the trade names Avandia, Avandamet and Avandaryl — violating the state’s Medical Assistance Programs Integrity Law and Unfair Trade Practices and Consumer Protections Law, among others.
The suit claims Louisiana’s Medicaid program paid GSK approximately $36,126,560 for fraudulently induced Avandia reimbursements. The suit seeks civil fines, civil penalties, restitution and other monetary relief.
In Oct. 2010, GSK agreed to pay $750 million to settle allegations that it manufactured and sold contaminated drugs to Medicaid and other government health programs.
Read the release on Louisiana’s Attorney General and GlaxoSmithKline.
Read more about healthcare and Medicaid fraud:
–Louisiana AG Accuses 18 Drugmakers of Overcharging Medicaid
–20 Largest False Claims Cases of 2010
–11 Things to Know About the False Claims Act
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
